The Global Pharmaceutical Excipients For Injection Market was valued at USD 1,627 Million in 2025 and is projected to reach USD 2,780 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period (2025–2034). This growth is being driven by the surging demand for parenteral drug delivery systems, the rapid expansion of biopharmaceutical production, and the accelerating adoption of advanced sterile excipient technologies across commercial and clinical pharmaceutical sectors.

As the pharmaceutical industry transforms toward precision medicine, complex biologics, and patient-centric injectable therapies, the spotlight is on the key excipient suppliers who are driving innovation, purity, and formulation excellence. In this blog, we profile the Top 10 Companies in the Pharmaceutical Excipients For Injection Industry—a mix of global chemical leaders, specialty manufacturers, and biotech-focused innovators shaping the future of sterile injectable drug development.

---

📺 1. Dow Chemical Company

Headquarters: Midland, Michigan, USA
Key Offering: High-purity solvents, solubilizers, and injectable-grade excipient systems

Dow Chemical Company stands as the market leader in pharmaceutical excipients for injection, commanding approximately 18% of global revenue in 2024. Its extensive chemical manufacturing infrastructure and diversified excipient portfolio make it the go-to partner for sterile drug formulators worldwide. Dow’s injectable-grade offerings are formulated to meet the most stringent pharmacopeial specifications, including USP, Ph. Eur., and JP standards, ensuring compatibility with a wide range of active pharmaceutical ingredients (APIs) used in parenteral therapies.

Innovation Highlights:

• Strategic investments in high-purity injectable excipient grades for biologics manufacturing

• Expanding GMP-certified production capacity to serve global sterile drug pipelines

• Partnerships with biopharma companies to co-develop next-generation formulation systems

Download FREE Sample Report:
Pharmaceutical Excipients For Injection Market – View in Detailed Research Report

---

� 2. Nippon Fine Chemical

Headquarters: Osaka, Japan
Key Offering: Specialized solubilizers, lipid-based excipients, and pH adjusters

Nippon Fine Chemical has carved out a strong competitive position in the Asian pharmaceutical excipients market, holding an estimated 12% global share. The company’s strength lies in its highly specialized solubilizers and pH-adjusting agents that are critical for stabilizing complex biologic formulations. Its focus on lipid-based injectable systems has positioned Nippon Fine Chemical as a preferred partner for Japanese and pan-Asian biopharma manufacturers developing oncology and autoimmune therapies.

Innovation Highlights:

• Advanced lipid excipient platforms designed for mRNA and gene therapy applications

• Continuous R&D investment in novel solubilization technologies for poorly soluble APIs

• Expansion into European and North American markets through strategic distribution alliances

---

� 3. NOF Corporation

Headquarters: Tokyo, Japan
Key Offering: PEGylation reagents, phospholipids, and lipid-based excipients for injectables

NOF Corporation is a globally recognized specialist in lipid chemistry, offering a comprehensive portfolio of phospholipids and PEGylation reagents that are indispensable in the formulation of liposomal drug delivery systems and lipid nanoparticles. The company’s excipients have been integral to mRNA vaccine development platforms, gaining significant attention following their critical role in COVID-19 vaccine formulations. NOF continues to expand its production capacity to meet the growing demand from gene therapy and advanced biologics pipelines.

Innovation Highlights:

• High-purity GMP-grade phospholipids widely used in liposomal injectable formulations

• PEGylation technology platforms enabling extended drug circulation and reduced immunogenicity

• Dedicated manufacturing lines for lipid nanoparticle excipients supporting nucleic acid therapies

Download FREE Sample Report:
Pharmaceutical Excipients For Injection Market – View in Detailed Research Report

---

� 4. Croda International

Headquarters: Snaith, East Yorkshire, United Kingdom
Key Offering: Excipients for drug solubilization, stabilization, and lipid nanoparticle systems

Croda International has significantly strengthened its position in the pharmaceutical excipients space through targeted acquisitions and a focused innovation pipeline. The company’s Crodarom and Cithrol product families serve as critical solubilization and emulsification agents in sterile injectable formulations. Croda’s strategic acquisition of Avanti Polar Lipids further cemented its leadership in the lipid excipient segment, making it one of the most well-rounded suppliers for advanced biologics and nucleic acid therapeutics globally.

Innovation Highlights:

• Avanti Polar Lipids acquisition expanding lipid nanoparticle excipient capabilities for RNA therapies

• High-performance injectable-grade polysorbates meeting stringent endotoxin and purity standards

• Active collaboration with biopharma firms on next-generation parenteral delivery systems

---

� 5. Pfanstiehl Laboratories

Headquarters: Waukegan, Illinois, USA
Key Offering: Ultra-high-purity excipients for biologics, mRNA vaccines, and cell & gene therapies

Pfanstiehl Laboratories occupies a unique position in the pharmaceutical excipients market as a specialist in ultra-high-purity excipients designed specifically for the most demanding injectable applications. The company has been a trusted supplier of sucrose, trehalose, and other stabilizing agents used in lyophilized biologics. Pfanstiehl’s role in the mRNA vaccine supply chain during the COVID-19 pandemic underscored its importance as a critical materials partner for next-generation injectable therapeutics, and the company continues to scale capacity to meet sustained demand.

Innovation Highlights:

• Ultra-high-purity sucrose and trehalose recognized as critical cryoprotectants in biologic lyophilization

• GMP manufacturing infrastructure tailored for cell and gene therapy excipient requirements

• Strategic capacity expansions to meet growing demand from mRNA vaccine and biologic pipelines

Download FREE Sample Report:
Pharmaceutical Excipients For Injection Market – View in Detailed Research Report

---

� 6. Nanjing Well Pharmaceutical

Headquarters: Nanjing, Jiangsu, China
Key Offering: Injectable-grade solvents, solubilizers, and antioxidants

Nanjing Well Pharmaceutical is among the most prominent Chinese manufacturers of pharmaceutical excipients for injection, benefiting from strong domestic demand and government-backed initiatives to localize the pharmaceutical supply chain. The company supplies a broad portfolio of injectable-grade excipients including propylene glycol, ethanol, and polysorbate-based solubilizers that are increasingly exported to emerging markets. Its cost-competitive manufacturing model and compliance with Chinese GMP standards have made it a significant player across Asia-Pacific markets.

Innovation Highlights:

• Expanding export capabilities to Southeast Asia, the Middle East, and Latin America

• Investment in upgraded quality control systems to meet international pharmacopeial standards

• Collaboration with domestic biopharma firms on excipient development for biologics formulations

---

� 7. Jiangsu Maxim Biological

Headquarters: Jiangsu, China
Key Offering: Biological excipients, stabilizers, and preservative-free injectable systems

Jiangsu Maxim Biological specializes in biologically derived excipients and stabilizing agents for parenteral formulations, with a particular focus on preservative-free systems that are increasingly preferred in modern injectable drug design. The company has developed proprietary excipient blends that minimize injection-site irritation while maintaining sterility assurance. Its growth trajectory has been supported by China’s booming biologics sector and increasing domestic regulatory alignment with international standards, positioning Jiangsu Maxim as a rising force in the global excipients landscape.

Innovation Highlights:

• Development of preservative-free excipient systems tailored for prefilled syringe applications

• Proprietary stabilizer blends offering improved protein aggregation prevention in biologic injectables

• Alignment with ICH Q3D elemental impurity guidelines for export-oriented product lines

---

� 8. Jiangsu Poly Pharmaceutical

Headquarters: Jiangsu, China
Key Offering: Pharmaceutical-grade solvents, tonicity agents, and pH buffering systems

Jiangsu Poly Pharmaceutical has established itself as a reliable supplier of core injectable excipients, including tonicity agents such as sodium chloride and mannitol, as well as phosphate and citrate buffering systems critical for maintaining pH stability in parenteral formulations. The company’s production volumes are substantial, serving both domestic generic injectable manufacturers and international partners seeking cost-effective, quality-assured excipient supply. With ongoing investments in regulatory compliance, Jiangsu Poly is steadily building credibility in regulated Western markets.

Innovation Highlights:

• High-volume production of mannitol and sodium chloride meeting USP and Ph. Eur. specifications

• Development of ready-to-use buffer concentrate systems for streamlined sterile manufacturing

• Active pursuit of Drug Master File (DMF) registrations in the U.S. and European markets

---

� 9. Er Kang Pharmaceutical

Headquarters: Hunan, China
Key Offering: Cyclodextrins, solubilization excipients, and injectable-grade bulking agents

Er Kang Pharmaceutical is a recognized specialist in cyclodextrin-based excipients, which are widely used to enhance the aqueous solubility of poorly water-soluble APIs in injectable formulations. Cyclodextrins have become increasingly important as the pharmaceutical industry develops more complex small molecules and repurposed drugs that require solubilization support. Er Kang’s hydroxypropyl-beta-cyclodextrin (HP-β-CD) product line is used in both approved injectable drugs and investigational compounds undergoing clinical trials globally.

Innovation Highlights:

• Specialized HP-β-CD manufacturing with rigorous control of substitution degree and purity profiles

• Supply partnerships with international drug developers for cyclodextrin-complexed injectable formulations

• Ongoing R&D into modified cyclodextrin variants for targeted and controlled-release parenteral applications

---

� 10. Guangzhou Hanfang Pharmaceutical

Headquarters: Guangzhou, Guangdong, China
Key Offering: Traditional Chinese medicine injection excipients and botanical-derived stabilizers

Guangzhou Hanfang Pharmaceutical occupies a distinctive niche within the pharmaceutical excipients for injection market, specializing in excipients and formulation aids used in traditional Chinese medicine (TCM) injectable preparations. As TCM injections remain a significant therapeutic category within China’s healthcare system, Hanfang plays a critical supporting role in ensuring the stability, safety, and regulatory compliance of these formulations. The company’s expertise in botanical-derived excipients and their compatibility with complex phytochemical extracts sets it apart from conventional excipient manufacturers.

Innovation Highlights:

• Dedicated excipient portfolio developed for the unique formulation challenges of TCM injectables

• Compliance with China’s National Medical Products Administration (NMPA) standards for injectable excipients

• Research programs aimed at improving safety profiles of botanical-derived injectable formulations

Read Full Report:
Pharmaceutical Excipients For Injection Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Pharmaceutical Excipients For Injection Is Smarter and More Specialized

The pharmaceutical excipients for injection market is undergoing a significant transformation. While conventional solvents and tonicity agents continue to anchor the market by volume, the industry is investing heavily in next-generation excipient technologies—from lipid nanoparticle systems and cyclodextrin complexation to smart pH-responsive polymers and ultra-high-purity cryoprotectants for advanced biologics.

📈 Key Trends Shaping the Market:

• Rapid expansion of lipid-based excipient platforms driven by mRNA therapeutics and gene therapy pipelines

• Rising demand for preservative-free and single-dose injectable excipient systems aligned with patient safety priorities

• Regulatory harmonization across major markets driving higher purity and traceability standards for injectable excipients

• Strategic alliances between excipient manufacturers and biopharma companies for co-development of formulation-ready materials

• Asia-Pacific emerging as both a production hub and a major demand center, accounting for a growing share of global injectable excipient consumption

Read Full Report:
Pharmaceutical Excipients For Injection Market – View in Detailed Research Report

The companies profiled above are not only enabling the global production of life-saving injectable medicines—they are spearheading the next wave of pharmaceutical innovation, from precision biologics to transformative gene therapies, one excipient at a time.